[go: up one dir, main page]

Pitman et al., 2010 - Google Patents

Inhibitors of the sphingosine kinase pathway as potential therapeutics

Pitman et al., 2010

Document ID
7350265923058759607
Author
Pitman M
Pitson S
Publication year
Publication venue
Current cancer drug targets

External Links

Snippet

Sphingosine kinase (SK) 1 and 2 are lipid kinases that phosphorylate sphingosine to form sphingosine-1 phosphate, a potent signalling molecule with pleiotrophic effects. SK1 is commonly up-regulated in tumours and its inhibition or genetic ablation has been shown to …
Continue reading at www.ingentaconnect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P-C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates

Similar Documents

Publication Publication Date Title
Pitman et al. Inhibitors of the sphingosine kinase pathway as potential therapeutics
Wang et al. Roles of sphingosine-1-phosphate signaling in cancer
Gangoiti et al. Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease
Fabrias et al. Dihydroceramide desaturase and dihydrosphingolipids: debutant players in the sphingolipid arena
Park et al. The role of sphingolipids in endoplasmic reticulum stress
Saddoughi et al. Roles of bioactive sphingolipids in cancer biology and therapeutics
Huang et al. Roles of sphingosine 1-phosphate on tumorigenesis
Knapp Cardioprotective role of sphingosine-1-phosphate
Schiffmann et al. Inhibitors of specific ceramide synthases
Cuvillier et al. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting
Delgado et al. Sphingolipid modulation: a strategy for cancer therapy
Canals et al. Novel chemotherapeutic drugs in sphingolipid cancer research
Jamil et al. Sphingolipids in mitochondria—from function to disease
WO2016044467A1 (en) Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
M Pitson et al. Regulation of sphingosine kinase in hematological malignancies and other cancers
JP6617702B2 (en) FTY720 azacyclic constraint analog
C Loh et al. Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond
Padrón Sphingolipids in anticancer therapy
JP2017507930A (en) Combination of an IKKε / TBK1 inhibitor and a beta-adrenergic agonist or sympathetic nervous system activator
Brice et al. Sphingolipid metabolism and analysis in metabolic disease
Morales et al. Pharmacological modulation of sphingolipids and role in disease and cancer cell biology
Ballereau et al. Alteration of ceramide 1-O-functionalization as a promising approach for cancer therapy
US9345710B2 (en) Inhibitors of phosphatidic acid phosphohydrolase (PAP) enzymes for the treatment of cancers that depend on members of the ErbB/HER tyrosine kinase receptor family
Albi et al. Sphingolipid metabolism inhibitors and cell function
Gupta et al. Targeting the sphingosine kinase/sphingosine-1-phosphate signaling axis in drug discovery for cancer therapy. Cancers. 2021; 13: 1898